Myriad Genetics, Inc. (NASDAQ:MYGN) Receives $23.17 Consensus PT from Brokerages

Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) have been given an average recommendation of “Hold” by the six research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $23.17.

A number of research analysts recently weighed in on the company. Piper Sandler assumed coverage on Myriad Genetics in a research note on Thursday, December 21st. They issued a “neutral” rating and a $23.00 price objective on the stock. The Goldman Sachs Group raised their price objective on Myriad Genetics from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, January 29th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in MYGN. China Universal Asset Management Co. Ltd. increased its position in Myriad Genetics by 96.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,101 shares of the company’s stock worth $34,000 after buying an additional 1,032 shares during the period. Royal Bank of Canada grew its holdings in shares of Myriad Genetics by 29.0% during the 3rd quarter. Royal Bank of Canada now owns 2,339 shares of the company’s stock worth $44,000 after purchasing an additional 526 shares in the last quarter. Natixis acquired a new stake in shares of Myriad Genetics during the 4th quarter worth approximately $44,000. Point72 Hong Kong Ltd grew its holdings in shares of Myriad Genetics by 722.8% during the 2nd quarter. Point72 Hong Kong Ltd now owns 3,217 shares of the company’s stock worth $58,000 after purchasing an additional 2,826 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Myriad Genetics by 99.8% during the 1st quarter. Tower Research Capital LLC TRC now owns 2,654 shares of the company’s stock worth $62,000 after purchasing an additional 1,326 shares in the last quarter. 99.02% of the stock is owned by institutional investors.

Myriad Genetics Trading Down 0.7 %

Shares of NASDAQ MYGN opened at $18.51 on Tuesday. Myriad Genetics has a one year low of $13.82 and a one year high of $24.21. The firm has a market capitalization of $1.66 billion, a PE ratio of -5.78 and a beta of 1.95. The company has a current ratio of 2.01, a quick ratio of 1.87 and a debt-to-equity ratio of 0.05. The business has a 50-day moving average price of $21.61 and a two-hundred day moving average price of $19.46.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Tuesday, February 27th. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. Myriad Genetics had a negative return on equity of 8.03% and a negative net margin of 34.96%. The company had revenue of $196.60 million during the quarter, compared to the consensus estimate of $194.80 million. During the same period last year, the business earned ($0.20) EPS. The business’s quarterly revenue was up 10.6% on a year-over-year basis. As a group, analysts predict that Myriad Genetics will post -0.36 earnings per share for the current fiscal year.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.